
Capitainer AB
Capitainer has developed a patented cutting-edge solution for blood and plasma sampling. The company’s innovative technology is designed for user-friendly remote sampling with clinical-quality results.
Learn more about our ongoing investments. We have made our analysis, negotiated the terms and made our decision. We have compiled the information and documents for you to make your decision.

Capitainer has developed a patented cutting-edge solution for blood and plasma sampling. The company’s innovative technology is designed for user-friendly remote sampling with clinical-quality results.
Sciety’s portfolio consists of companies that develop and commercialise solutions based on vital innovations. These range from personalised treatments for serious diseases to blood-based diagnostics for early cancer detection, and digital tools that support emergency care and surgery.
We focus on companies with scalable solutions to medical challenges where there is a clear clinical need and strong commercial potential. We also invest in companies developing research and development tools that can accelerate medical breakthroughs and create significant value for society.

PeptiSystems has developed a groundbreaking technology for the large-scale production of precision drugs. The company sells instruments for manufacturing peptides and oligonucleotides used in pharmaceutical manufacturing.

Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.

Capitainer develops and sells intelligent solutions for self-sampling blood, plasma, and urine. The products enable easy home sampling with market-leading precision, delivering value across the entire care chain.

NEOGAP Therapeutics develops a new type of personalised therapy for the treatment of cancer. The company uses proprietary machine learning algorithms and patented technology to tailor the treatment for each patient and its specific tumour cells.
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.

Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.